doi: 10.3389/fonc.2022.917634 Received 11 April 2022 Accepted 13 May 2022 Published 27 June 2022 Volume 12 - 2022 Edited by Eduard Yakubov, Paracelsus Medical Private University, Germany Reviewed by Aayushi Mahajan, Columbia University, United States
Diabetes Obes Metab (2021) 23(1):13646
Long-term safety data The most compelling safety evidence comes from a 15-year follow-up study on long-term epithalamin treatment
Research indicates that GLP-1 receptor agonists, including semaglutide, do not suppress testosterone production or damage sperm directly, making them a viable option for men seeking sustainable weight loss without sacrificing reproductive capacity
Their Womens Clinical Health Team offers specialized support to healthcare providers
This medication belongs to a class called GLP-1 receptor agonists